



www.genfit.com

GENFIT: PUBLICATION OF GFT505 CLINICAL RESULTS IN “DIABETES CARE”

- **After critical review by independent experts, the results of the GFT505-209-3 and GFT505-209-4 studies are published in « *Diabetes Care* », an official international scientific journal of the ADA (American Diabetes Association).**

Lille, France, and Cambridge, Mass., September 6th, 2011 – GENFIT (Alternext: ALGFT; ISIN: FR0004163111), a biopharmaceutical company at the forefront of drug discovery and development, focused on the early diagnosis and preventive treatment of cardiometabolic and associated disorders, today announced the publication in « *Diabetes Care* » of a scientific article presenting the results of the GFT505-210-3 and GFT505-210-4 clinical trials.

The article reports the beneficial effects of GFT505 on glucose and lipid metabolism, inflammation, and liver function in patients with abdominal obesity, mixed dyslipidemia, and/or pre-diabetes.

After critical review and approval by independent experts, the manuscript is published under the title ‘Effects of the new dual PPAR α / δ agonist GFT505 on lipid and glucose homeostasis in abdominally obese patients with combined dyslipidemia or impaired glucose metabolism » (B. Cariou, Y. Zair, B. Staels, and E. Bruckert, *Diabetes Care*, 34: 2008-2014) in the category « Emerging Treatments and Technologies’.

« *Diabetes Care* » is a prestigious international scientific journal for the health care practitioner that aims to increase knowledge, stimulate research, and promote better management of people with diabetes. The journal publishes original research on human studies in the following five categories: 1) *Clinical Care/Education/Nutrition/Psychosocial Research*, 2) *Epidemiology/Health Services Research*, 3) *Emerging Treatments and Technologies*, 4) *Pathophysiology/Complications*, and 5) *Cardiovascular and Metabolic Risk*.

Prof. Bertrand Cariou, Diabetologist at Nantes University Hospital and first author of the article, declared: «This publication in an internationally renowned scientific journal such as « *Diabetes Care* » confirms the strong interest of the scientific community for GFT505 in the management of diabetic patients. I hope that readers will be convinced by the potential of this new molecule for the prevention of cardiovascular events and the treatment of hepatic disorders (NAFLD/NASH) linked to diabetes. »

About GENFIT:

GENFIT is a biopharmaceutical company focused on the Discovery and Development of drug candidates in therapeutic fields linked to cardiometabolic disorders (prediabetes/diabetes, atherosclerosis, dyslipidemia, inflammatory diseases...). GENFIT uses a multi-pronged approach based on early diagnosis, preventive solutions, and therapeutic treatments and advances therapeutic research programs, either independently or in partnership with leading pharmaceutical companies (SANOFI, SERVIER, ...), to address these major public health concerns and their unmet medical needs. GENFIT’s research programs have resulted in the creation of a rich and diversified pipeline of drug candidates at different stages of development, including GENFIT’s lead proprietary compound, GFT505, that is currently in Phase II.

With facilities in Lille, France, and Cambridge, MA (USA), the Company has approximately 100 employees. GENFIT is a public company listed on the Alternext trading market by Euronext™ Paris (Alternext: ALGFT; ISIN: FR0004163111). www.genfit.com

Contacts:

GENFIT

Jean-François Mouney – CEO & Chairman of the Management Board
+33 (0)3 2016 4000

MILESTONES – Press Relations

Bruno Arabian
+33 (0)1 75 44 87 40 / +33 (0)6 87 88 47 26 – barabian@milestones.fr